Tags

Type your tag names separated by a space and hit enter

Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Mov Disord. 1997 Jan; 12(1):33-8.MD

Abstract

We used [11C]raclopride (RACLO) and positron emission tomography (PET) to study longitudinally striatal dopamine D2 receptor binding in nine patients with Parkinson's disease (PD) at an early drug-naive stage and 3-5 years later, when motor fluctuations had appeared in seven of them. Patients were treated with a combination of levodopa and dopamine agonists. Data were compared with 10 healthy controls in the same age range. Initially, patients with PD showed a significant increase of RACLO uptake in the putamen compared with controls (p < 0.04). The caudate nucleus revealed values in the normal range. After 3-5 years, RACLO binding was significantly reduced in the putamen (p < 0.03) and caudate nucleus (p < 0.03) compared with baseline. Values were now in the control range in the putamen and reduced in the caudate nucleus (p < 0.05). The clinical score at "off" had significantly worsened (p < 0.0005) compared with the first PET scan. The nine PD patients reported here had already been investigated 3-4 months after therapy began and that time did not show a reduction of the initially increased RACLO binding capacity (data published previously). These results indicate long-term downregulation of striatal dopamine D2 receptor binding in PD. Receptor changes in the striatum of patients with PD may be induced by chronic dopaminergic therapy or occur independently of treatment, as a result of structural adaptation of the postsynaptic dopaminergic system to the progressive decline of nigrostriatal neurons.

Authors+Show Affiliations

PET Department, Paul Scherrer Institute, Villigen, Switzerland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8990051

Citation

Antonini, A, et al. "Long-term Changes of Striatal Dopamine D2 Receptors in Patients With Parkinson's Disease: a Study With Positron Emission Tomography and [11C]raclopride." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 12, no. 1, 1997, pp. 33-8.
Antonini A, Schwarz J, Oertel WH, et al. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov Disord. 1997;12(1):33-8.
Antonini, A., Schwarz, J., Oertel, W. H., Pogarell, O., & Leenders, K. L. (1997). Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Movement Disorders : Official Journal of the Movement Disorder Society, 12(1), 33-8.
Antonini A, et al. Long-term Changes of Striatal Dopamine D2 Receptors in Patients With Parkinson's Disease: a Study With Positron Emission Tomography and [11C]raclopride. Mov Disord. 1997;12(1):33-8. PubMed PMID: 8990051.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. AU - Antonini,A, AU - Schwarz,J, AU - Oertel,W H, AU - Pogarell,O, AU - Leenders,K L, PY - 1997/1/1/pubmed PY - 1997/1/1/medline PY - 1997/1/1/entrez SP - 33 EP - 8 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 12 IS - 1 N2 - We used [11C]raclopride (RACLO) and positron emission tomography (PET) to study longitudinally striatal dopamine D2 receptor binding in nine patients with Parkinson's disease (PD) at an early drug-naive stage and 3-5 years later, when motor fluctuations had appeared in seven of them. Patients were treated with a combination of levodopa and dopamine agonists. Data were compared with 10 healthy controls in the same age range. Initially, patients with PD showed a significant increase of RACLO uptake in the putamen compared with controls (p < 0.04). The caudate nucleus revealed values in the normal range. After 3-5 years, RACLO binding was significantly reduced in the putamen (p < 0.03) and caudate nucleus (p < 0.03) compared with baseline. Values were now in the control range in the putamen and reduced in the caudate nucleus (p < 0.05). The clinical score at "off" had significantly worsened (p < 0.0005) compared with the first PET scan. The nine PD patients reported here had already been investigated 3-4 months after therapy began and that time did not show a reduction of the initially increased RACLO binding capacity (data published previously). These results indicate long-term downregulation of striatal dopamine D2 receptor binding in PD. Receptor changes in the striatum of patients with PD may be induced by chronic dopaminergic therapy or occur independently of treatment, as a result of structural adaptation of the postsynaptic dopaminergic system to the progressive decline of nigrostriatal neurons. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/8990051/Long_term_changes_of_striatal_dopamine_D2_receptors_in_patients_with_Parkinson's_disease:_a_study_with_positron_emission_tomography_and_[11C]raclopride_ L2 - https://doi.org/10.1002/mds.870120107 DB - PRIME DP - Unbound Medicine ER -